← back to search

Thijs Beuming

Schrodinger (United States) · US
Area of research
Molecular Biology · Computational Theory and Mathematics
Research interest
Research interests include Receptor Mechanisms and Signaling, Protein Structure and Dynamics, Computational Drug Discovery Methods, and Neuroscience and Neuropharmacology Research.
h-index
35
citations
6,782
works
64
NIH funding
primary concept
email

Recent publications

Are Deep Learning Structural Models Sufficiently Accurate for Virtual Screening? Application of Docking Algorithms to AlphaFold2 Predicted Structures.
2023cited by 54position: contributordoi
Structure-Activity Relationship Studies of Antimalarial <i>Plasmodium</i> Proteasome Inhibitors─Part II.
2023cited by 10position: contributordoi
Are Deep Learning Structural Models Sufficiently Accurate for Free-Energy Calculations? Application of FEP+ to AlphaFold2-Predicted Structures.
2022cited by 36position: contributordoi
Are Deep Learning Structural Models Sufficiently Accurate for Virtual Screening? Application of Docking Algorithms to AlphaFold2 Predicted Structures
2022cited by 2position: contributordoi
Are Deep Learning Structural Models Sufficiently Accurate for Free Energy Calculations? Application of FEP+ to AlphaFold2 Predicted Structures
2022cited by 2position: contributordoi
Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
Nature Communications 2019cited by 146position: middledoi
Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field
Journal of the American Chemical Society 2015cited by 1,370position: middledoi
What Can Crystal Structures of Aminergic Receptors Tell Us about Designing Subtype-Selective Ligands?
Pharmacological Reviews 2014cited by 126position: middledoi
Discovery and Characterization of a G Protein–Biased Agonist That Inhibits β-Arrestin Recruitment to the D2 Dopamine Receptor
Molecular Pharmacology 2014cited by 84position: middledoi
Ligand-Dependent Activation and Deactivation of the Human Adenosine A<sub>2A</sub>Receptor
Journal of the American Chemical Society 2013cited by 110position: middledoi
Predicting GPCR Promiscuity Using Binding Site Features
Journal of Chemical Information and Modeling 2013cited by 22position: middledoi
Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor
Journal of Medicinal Chemistry 2012cited by 178position: middledoi
Steric Hindrance Mutagenesis in the Conserved Extracellular Vestibule Impedes Allosteric Binding of Antidepressants to the Serotonin Transporter
Journal of Biological Chemistry 2012cited by 95position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 4 papers (2022–2023)Lei Shi · National Institute on Drug Abuse4 papers (2012–2014)Vı́ctor Guallar · Institució Catalana de Recerca i Estudis Avançats3 papers (2022–2023)Amy Hauck Newman · Target (United States)3 papers (2012–2014)Jonathan A. Javitch · Columbia University Irving Medical Center3 papers (2012–2014)Anna M. Díaz-Rovira · Barcelona Supercomputing Center3 papers (2022–2023)Lucía Díaz · Universitat Politècnica de Catalunya3 papers (2022–2023) · 3 papers (2022–2023)Helena Martín · ESCI-UPF3 papers (2022–2023)Mayako Michino · Cancer Research Center2 papers (2012–2014)Soumya S. Ray · Capital One (United States)2 papers (2022–2022)Prashant Donthamsetti · Vanderbilt University2 papers (2012–2014)Lani S. Chun · National Institutes of Health1 papers (2014–2014)Adrian Padron · Meharry Medical College1 papers (2014–2014) · 1 papers (2013–2013)Jerez A. Te · Henry M. Jackson Foundation1 papers (2012–2012)Brittney Miller · Center for Theoretical Biological Physics1 papers (2014–2014)Ashwini K. Banala · Columbia University1 papers (2012–2012)Julie A. Meade · Virginia Commonwealth University1 papers (2014–2014)Robert R. Luedtke · University of North Texas1 papers (2012–2012)